Peptide Applications

Obesity has become a globally prevalent chronic disease, affecting approximately 650 million adults worldwide. It is closely associated with various complications, including cardiovascular disease, type 2 diabetes, and hypertension. A weight reduction of 5% or more can improve these associated health risks. While lifestyle intervention forms the cornerstone of obesity treatment, its weight loss effects are often limited and prone to rebound. Anti-obesity medications (AOMs) have therefore emerged as an important adjunctive treatment. Semaglutide, a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist, was approved by the US FDA in 2021 for chronic weight management. With its significant weight loss efficacy and cardiovascular protective properties, it represents a major breakthrough in obesity treatment. This article provides a systematic review of the mechanism of action, weight loss and cardiometabolic efficacy, and safety profile of semaglutide 2.4 mg/week for obesity treatment. By analyzing key clinical trials (the STEP program), it evaluates its clinical application value and future directions, offering a comprehensive reference for the pharmacotherapy of this chronic disease.

Semaglutide, a GLP-1 receptor agonist, is widely used for its significant efficacy in treating type 2 diabetes and promoting weight loss, and is even prescribed off-label for weight management in non-diabetic individuals. However, with its surging usage (e.g., in the US, the number of users increased from 569 in 2019 to 22,891 in 2022), aesthetic-related side effects such as "Ozempic face" have garnered increasing attention. This article focuses on the facial and dermatological aesthetic issues induced by semaglutide, their underlying causes, and corresponding management and repair strategies, providing a reference for clinical consultation and users.

The self-assembly of bioactive peptides has become a research hotspot and a central direction in food science. Its core value lies in the spontaneous formation of ordered nanostructures—such as nanofibers, micelles, and hydrogels—which precisely addresses the industry's key challenges of gastrointestinal degradation and low bioavailability of functional compounds. This opens a new path for the development of precision nutrition foods and the innovative design of functional carriers. However, challenges such as unclear in vivo behavior and unverified safety remain. The following sections will elaborate on the practical value and application potential of peptide self-assembly in the food sector, focusing on its underlying principles, core advantages, application scenarios, and developmental challenges.

Today, we share an important study led by Professor Runhui Liu's team at East China University of Science and Technology, published in Nature Biotechnology. This research addresses the global challenge of limited efficacy in treating systemic fungal infections (especially meningitis) caused by inconsistent in vivodistribution of synergistic antifungal drugs. The team developed a host defense peptide-mimetic self-assembling micelle delivery system. This strategy involves a bifunctional polymer possessing both antifungal activity and self-assembly carrier capability, which efficiently encapsulates amphotericin B (AmB). This enables spatiotemporally consistent co-delivery of both drugs to the infection site. The system significantly reduces AmB toxicity, broadens its therapeutic window, and demonstrates efficacy superior to the clinical gold-standard therapy (AmBisome combined with 5-fluorocytosine) in mouse models of systemic candidiasis and cryptococcal meningitis. It offers a novel solution for tackling drug-resistant fungal infections.

GLP-1 drugs, as a novel class of therapies combining glucose-lowering, weight-loss, and anti-inflammatory effects, have expanded from their initial use in treating type 2 diabetes (T2D) to encompass obesity and various complications. They also show potential value in new indications such as neurodegenerative diseases and substance use disorders, thereby reshaping public health strategies for chronic disease intervention. This article systematically reviews the current application landscape, expansion directions, efficacy variations, safety profile, and future challenges of GLP-1 drugs, providing a comprehensive reference for understanding their clinical value and developmental potential.

Glucagon-like peptide-1 receptor agonists, as a key therapeutic approach for type 2 diabetes and obesity, have demonstrated significant efficacy in lowering blood glucose, promoting weight loss, improving insulin resistance, and exerting anti-inflammatory effects. Beyond their established role in metabolic disease management, their potential impact on cancer risk has become a focus of research. These agents act by activating the GLP-1 receptor or, in some cases, both the GLP-1R and the glucose-dependent insulinotropic polypeptide receptor. They may influence tumorigenesis and progression through both weight-dependent and weight-independent mechanisms. This article synthesizes relevant clinical evidence, mechanisms of action, and the current state of research to provide a core perspective on the potential anticancer properties of GLP-1R agonists.

In the field of biopharmaceuticals, protein and peptide drugs (PPs) hold a pivotal position in treating various diseases such as diabetes and osteoporosis, owing to their well-defined mechanisms of action, high selectivity, and low side effects. However, the traditional parenteral injection route not only causes pain and inconvenience to patients but may also lead to adverse reactions like subcutaneous nodules and infections, significantly impacting medication adherence. The oral route, as the most convenient and patient-preferred non-invasive administration method, can mimic the natural secretion process of proteins to potentially reduce side effects. Nevertheless, the complex physiological environment of the gastrointestinal (GI) tract presents multiple formidable barriers, resulting in extremely low oral bioavailability for PPs, which constitutes a major challenge for the pharmaceutical industry. This article provides a systematic analysis centered on the core obstacles, breakthrough strategies, current clinical application status, existing challenges, and future directions for oral PPs delivery, offering a clear framework for research and development in this field.